But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.